A study done by researchers at University Medical Center Groningen (UMCG) shows increased risk of stroke or heart attack to an individual if the blood group of that particular individual is not "O" group. Researchers observed 14 heart attacks in 1000 individuals belonging to "O" blood group compared to 15 heart attacks in 1000 individuals other than "O" blood group. Those individuals with blood group other than "O" are at higher risk of heart diseases. Scientists think that other blood groups may contain higher levels of blood clotting protein. Authors of the study say that the cardiovascular risk assessment report of an individual should contain blood group other than "O" group as a risk factor. Author of the study was Tessa Kole, from the University Medical Center Groningen (UMCG) the Netherlands and the study findings were presented at the European Society of Cardiology.
An earlier research done by researchers from UT Southwestern Medical Center, Texas, United States shows prevention of high blood sugar or glucose levels by inhibiting glucagon receptors. They hypothesized that type 1 diabetes (T1D) and type 2 diabetes (T2D) could be treated by blocking the action of glucagon.
In a current study done by researchers at UT Southwestern Medical Center, United States shows new diabetes treatment by regulating blood sugar levels with ghrelin hormone. Ghrelin was not studied much earlier but they say ghrelin hormone works by preventing actions of glucagon and insulin.
Researchers studied the role of ghrelin hormone in those mice models which are lacking with glucagon receptors. Researchers destroyed insulin-producing beta cells in mice models and tried to make them diabetic. Researchers found that even though there is no production of insulin, diabetes did not develop in them. Their ghrelin hormone levels were high and blood sugar or glucose levels are normal. Mice models experienced hypoglycemia when researchers blocked high levels of ghrelin hormone.
The study findings indicate that hypoglycemia can be prevented by blocking glucagon activity as ghrelin rise with reduced glucagon. Researchers say new treatments can be developed to prevent hypoglycemia by targeting glucagon receptors. Senior author of the study was Dr. Jeffrey M Zigman, an Endocrinologist, UT Southwestern Medical Center, Texas, the United States and the study findings were published in the journal Diabetes Care.
Ghrelin : Also known as lenomorelin, a gastric hunger hormone produced in gastrointestinal tract by ghrelinergic cells. Appetite is associated with this hormone.
Glucagon : Glucagon is a peptide hormone produced in the pancreas by alpha cells. This hormone increases glucose or sugar levels in the bloodstream and also keeps them stable. Consumption of glucose by the liver will be prevented by this hormone. The function of glucagon is opposite to that of insulin's function.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.